002399 海普瑞
已收盘 04-10 15:00:00
资讯
新帖
简况
股市必读：海普瑞（002399）4月8日董秘有最新回复
证券之星 · 04-09 01:14
股市必读：海普瑞（002399）4月8日董秘有最新回复
海普瑞：公司对于Kymab、君圣泰等相关投资均取得了较好的收益表现
证券之星 · 04-03
海普瑞：公司对于Kymab、君圣泰等相关投资均取得了较好的收益表现
商业化与平台能力加速升级 解锁海普瑞长期增长密码
中金财经 · 03-31
商业化与平台能力加速升级 解锁海普瑞长期增长密码
海普瑞(09989)发布年度业绩 股东应占溢利3.49亿元 同比减少45.96%
智通财经 · 03-30
海普瑞(09989)发布年度业绩 股东应占溢利3.49亿元 同比减少45.96%
股市必读：海普瑞（002399）3月23日收盘跌6.09%，主力净流入138.86万元
证券之星 · 03-24
股市必读：海普瑞（002399）3月23日收盘跌6.09%，主力净流入138.86万元
海普瑞遭洪泽君增持121.8万股 每股作价约5.51港元
新浪港股 · 02-04
海普瑞遭洪泽君增持121.8万股 每股作价约5.51港元
股东洪泽君增持海普瑞(09989)481.55万股 每股作价约5.49港元
智通财经网 · 02-02
股东洪泽君增持海普瑞(09989)481.55万股 每股作价约5.49港元
股市必读：海普瑞（002399）预计2025年全年每股收益盈利:0.1936元至0.2569元
证券之星 · 02-02
股市必读：海普瑞（002399）预计2025年全年每股收益盈利:0.1936元至0.2569元
海普瑞（002399）披露2025年度业绩预告，1月30日股价下跌0.72%
证券之星 · 01-30
海普瑞（002399）披露2025年度业绩预告，1月30日股价下跌0.72%
高基数下的正常回归，海普瑞归母净利润预减，扣非预增，主营业务有韧性
深圳商报·读创 · 01-30
高基数下的正常回归，海普瑞归母净利润预减，扣非预增，主营业务有韧性
海普瑞(09989)发盈警，预期年度归母净利润2.84亿元-3.77亿元 同比下降41.71%-56.09%
智通财经 · 01-30
海普瑞(09989)发盈警，预期年度归母净利润2.84亿元-3.77亿元 同比下降41.71%-56.09%
海普瑞全球肝素制剂业务拓展成效显著 全年业绩预期向好
美股速递 · 01-30
海普瑞全球肝素制剂业务拓展成效显著 全年业绩预期向好
海普瑞：公司始终以稳健经营，提升核心竞争力为根本，持续夯实内在价值
证券日报 · 01-19
海普瑞：公司始终以稳健经营，提升核心竞争力为根本，持续夯实内在价值
股市必读：海普瑞（002399）1月13日董秘有最新回复
证券之星 · 01-14
股市必读：海普瑞（002399）1月13日董秘有最新回复
海普瑞：公司将继续加强与资本市场投资者的沟通
证券日报 · 01-13
海普瑞：公司将继续加强与资本市场投资者的沟通
海普瑞选举张平为职工代表董事
财中社 · 2025-12-16
海普瑞选举张平为职工代表董事
较A股折价60%，肝素即将走出下行周期海普瑞(09989)现抄底信号？
智通财经 · 2025-12-06
较A股折价60%，肝素即将走出下行周期海普瑞(09989)现抄底信号？
海普瑞（002399）披露召开2025年第一次临时股东会通知，11月24日股价上涨1.21%
证券之星 · 2025-11-24
海普瑞（002399）披露召开2025年第一次临时股东会通知，11月24日股价上涨1.21%
海普瑞：关于独立董事任期届满离任暨补选独立董事的公告
证券日报 · 2025-11-24
海普瑞：关于独立董事任期届满离任暨补选独立董事的公告
海普瑞(09989)：建议选举浦洪为独立非执行董事
智通财经 · 2025-11-24
海普瑞(09989)：建议选举浦洪为独立非执行董事
加载更多
公司概况
公司名称：
深圳市海普瑞药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2010-05-06
主营业务：
深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投资，开发及商业化。公司的主要产品是依诺肝素钠制剂、肝素钠和依诺肝素钠原料药、分子药物CDMO服务。
发行价格：
148.00
{"stockData":{"symbol":"002399","market":"SZ","secType":"STK","nameCN":"海普瑞","latestPrice":11.28,"timestamp":1775804589000,"preClose":11.25,"halted":0,"volume":3829500,"delay":0,"changeRate":0.0027,"floatShares":1247000000,"shares":1467000000,"eps":0.0356,"marketStatus":"已收盘","change":0.03,"latestTime":"04-10 15:00:00","open":11.25,"high":11.48,"low":11.25,"amount":43423100,"amplitude":0.0204,"askPrice":11.3,"askSize":354,"bidPrice":11.28,"bidSize":139,"shortable":0,"etf":0,"ttmEps":0.0356,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"adjPreClose":11.25,"symbolType":"stock","openAndCloseTimeList":[[1775784600000,1775791800000],[1775797200000,1775804400000]],"highLimit":12.38,"lowLimit":10.13,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1467296204,"isCdr":false,"pbRate":1.37,"roa":"--","peRate":316.853933,"roe":"2.88%","epsLYR":0.2382,"committee":-0.07013,"marketValue":16551000000,"turnoverRate":0.0031,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-13。","hkstockBrief":{"symbol":"09989","market":"HK","secType":"STK","nameCN":"海普瑞","latestPrice":5.06,"timestamp":1775808558597,"preClose":5.08,"halted":0,"volume":295500,"delay":0,"premium":"-60.90"},"floatMarketCap":14068000000},"requestUrl":"/m/hq/s/002399","defaultTab":"news","newsList":[{"id":"2626264919","title":"股市必读：海普瑞（002399）4月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2626264919","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626264919?lang=zh_cn&edition=full","pubTime":"2026-04-09 01:14","pubTimestamp":1775668453,"startTime":"0","endTime":"0","summary":"截至2026年4月8日收盘，海普瑞报收于11.68元，上涨2.55%，换手率0.53%，成交量6.67万手，成交额7731.46万元。董秘最新回复投资者： 董秘你好，贵公司A股25年年报显示：原料药的全年毛利率为15.72%，25年半年报显示：原料药的毛利率为23.82%，原料药毛利率呈明显下降趋势。当日关注点来自交易信息汇总：4月8日主力资金净流入742.52万元，呈现主动买入态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900001043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","09989","BK0188","002399","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624658540","title":"海普瑞：公司对于Kymab、君圣泰等相关投资均取得了较好的收益表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2624658540","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624658540?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:00","pubTimestamp":1775199644,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞04月02日在投资者关系平台上答复投资者关心的问题。海普瑞回复：您好，公司2025年度归母净利润同比下降，主要是2024年同期存在大额一次性投资收益的正向影响，对本报告期归母净利润同比影响较大。投资收益方面，公司对于Kymab、君圣泰等相关投资均取得了较好的收益表现，未来公司将继续坚持理性分析、有效配置、前瞻规划的投资原则。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300023601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","09989","BK0188","002399","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623794773","title":"商业化与平台能力加速升级 解锁海普瑞长期增长密码","url":"https://stock-news.laohu8.com/highlight/detail?id=2623794773","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623794773?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:30","pubTimestamp":1774924201,"startTime":"0","endTime":"0","summary":"业绩增长的同时，海普瑞正持续升级工业化平台能力与全球商业化能力，以期实现公司长期高质量发展。报告期内，公司核心业务肝素制剂表现增长亮眼，依诺肝素钠制剂销量实现逾两成增长，全球收入两位数增长。另外，平台能力与智能制造建设也成为海普瑞未来高质量发展的关键因素，在市场看来，医药企业的智造能力是其全球竞争力的核心载体，并决定自身质量高度、成本优势与市场边界。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/31/20260331593458.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/31/20260331593458.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260331/32115066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","002399","BK0239","BK0070","09989","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623349539","title":"海普瑞(09989)发布年度业绩 股东应占溢利3.49亿元 同比减少45.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623349539","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623349539?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:24","pubTimestamp":1774880694,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)发布2025年度业绩，收入54.38亿元(人民币，下同)，同比增长3.41%;母公司拥有人应占溢利3.49亿元，同比减少45.96%;每股基本盈利0.24元，拟派末期现金股息每十股公司普通股1.45元(含税)。公告称，销售产品生产及销售的收入增加，主要由于报告期内药物制剂销量大幅增长所致。 毛利率的降低乃主要由于销售成本包含了存货跌价准备，由上年的人民币760万元增至人民币3650万元，及是受市场环境影响，原料药单价呈下行趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0070","BK0239","09989","BK0188","002399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621828900","title":"股市必读：海普瑞（002399）3月23日收盘跌6.09%，主力净流入138.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621828900","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621828900?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:33","pubTimestamp":1774297990,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，海普瑞报收于10.33元，下跌6.09%，换手率0.51%，成交量6.34万手，成交额6685.07万元。来自资金流向：3月23日主力资金净流入138.86万元，与前10个交易日主力资金累计净流出形成反差。交易信息汇总股价提醒3月23日海普瑞收盘报10.33元，跌6.09%，当日成交633.61万元。根据收盘数据统计，该股已连续3日下跌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400005092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","002399","BK0239","BK1191","BK0188","09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608812943","title":"海普瑞遭洪泽君增持121.8万股 每股作价约5.51港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608812943","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608812943?lang=zh_cn&edition=full","pubTime":"2026-02-04 08:04","pubTimestamp":1770163440,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，2月2日，洪泽君增持海普瑞（09989）121.8万股，每股作价5.509港元，总金额约为671万港元。增持后最新持股数目为2246.95万股，最新持股比例为10.20%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-02-04/doc-inhkrayr9887953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK0070","BK0239","002399","09989","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608863744","title":"股东洪泽君增持海普瑞(09989)481.55万股 每股作价约5.49港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608863744","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608863744?lang=zh_cn&edition=full","pubTime":"2026-02-02 19:06","pubTimestamp":1770030393,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，1月29日，股东洪泽君增持海普瑞(09989)481.55万股，平均每股作价为5.485港元，总金额约为2641.3万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260202/20260202190651_57581.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260202/20260202190651_57581.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["002399","BK0188","09989","BK0070","BK1191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608188136","title":"股市必读：海普瑞（002399）预计2025年全年每股收益盈利:0.1936元至0.2569元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608188136","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608188136?lang=zh_cn&edition=full","pubTime":"2026-02-02 04:14","pubTimestamp":1769976853,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，海普瑞报收于12.37元，下跌0.72%，换手率0.4%，成交量5.04万手，成交额6235.98万元。来自：海普瑞预计2025年全年扣非后净利润盈利3.62亿元至4.6亿元，同比增长42.78%至81.43%。海普瑞发布业绩预告，预计2025年全年归属净利润盈利2.84亿元至3.77亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002399","09989","BK0070","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607042932","title":"海普瑞（002399）披露2025年度业绩预告，1月30日股价下跌0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607042932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607042932?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:19","pubTimestamp":1769786351,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，海普瑞报收于12.37元，较前一交易日下跌0.72%，最新总市值为181.5亿元。该股当日开盘12.4元，最高12.52元，最低12.24元，成交额达6235.98万元，换手率为0.4%。近日，深圳市海普瑞药业集团股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为28,400万元至37,700万元，同比下降56.09%至41.71%，主要因上年同期存在超过3.5亿元的一次性投资收益导致基数较高。本次业绩预告数据未经会计师事务所审计，最终数据以2025年年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002399","09989","BK0070","BK0188","BK0239","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607046318","title":"高基数下的正常回归，海普瑞归母净利润预减，扣非预增，主营业务有韧性","url":"https://stock-news.laohu8.com/highlight/detail?id=2607046318","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607046318?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:32","pubTimestamp":1769779932,"startTime":"0","endTime":"0","summary":"1月30日晚间，海普瑞（002399）发布年度业绩预告，预计2025年全年归母净利润为28400万元~37700万元，同比预减41.71%~56.09%；预计2025年全年扣非净利润为36200万元~46000万元，同比预增42.78%~81.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637326839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09989","002399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607013138","title":"海普瑞(09989)发盈警，预期年度归母净利润2.84亿元-3.77亿元 同比下降41.71%-56.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607013138","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607013138?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:24","pubTimestamp":1769765086,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞 发布公告，该公司预计截至2025年12月31日止年度归属于上市公司股东的净利润人民币2.84亿元-人民币3.77亿元，同比下降41.71%-56.09%。报告期内，公司归属于上市公司股东的净利润同比有所下降，主要是去年同期存在超过人民币3.5亿元的一次性投资收益，从而形成了较高的基数。此外，报告期内本公司旗下联营公司因研发进展未达预期，预计将对本集团净利润造成一定影响，具体影响以会计师事务所最终确认为准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09989","002399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191734441","title":"海普瑞全球肝素制剂业务拓展成效显著 全年业绩预期向好","url":"https://stock-news.laohu8.com/highlight/detail?id=1191734441","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191734441?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:24","pubTimestamp":1769765042,"startTime":"0","endTime":"0","summary":"受益于全球肝素制剂业务扩张取得重大进展，海普瑞全年业绩表现值得期待。公司在国际化战略推进下，制剂板块增长动能持续释放，为整体盈利水平提供有力支撑。随着产能布局优化与市场渠道深化，其肝素产业链竞争力进一步凸显，未来业绩弹性有望增强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0070","BK0239","002399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604136825","title":"海普瑞：公司始终以稳健经营，提升核心竞争力为根本，持续夯实内在价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2604136825","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604136825?lang=zh_cn&edition=full","pubTime":"2026-01-19 21:09","pubTimestamp":1768828140,"startTime":"0","endTime":"0","summary":"证券日报网讯1月19日，海普瑞在互动平台回答投资者提问时表示，公司始终以稳健经营，提升核心竞争力为根本，持续夯实内在价值，并通过优化公司治理、加强信息披露、投资者关系管理、提高现金分红等方式不断完善市值管理工作，努力让公司价值获得更合理的市场体现，争取为投资者带来更好的回报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601193623547062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0239","002399","09989","BK1191","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603363743","title":"股市必读：海普瑞（002399）1月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603363743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603363743?lang=zh_cn&edition=full","pubTime":"2026-01-14 03:57","pubTimestamp":1768334229,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，海普瑞报收于12.43元，上涨0.73%，换手率0.5%，成交量6.26万手，成交额7838.59万元。董秘： 您好，公司2025年度具体经营业绩敬请关注公司2025年年度报告。股价受多种因素的影响，公司将继续加强与资本市场投资者的沟通，努力让公司内在价值更好地反映在资本市场的市值表现上，争取为投资者带来更好的回报。当日关注点来自交易信息汇总：1月13日主力资金净流入118.63万元，显示主力对海普瑞短期走势持积极态度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400003046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0070","09989","BK1191","002399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603470681","title":"海普瑞：公司将继续加强与资本市场投资者的沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2603470681","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603470681?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:40","pubTimestamp":1768308041,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，海普瑞在互动平台回答投资者提问时表示，公司2025年度具体经营业绩敬请关注公司2025年年度报告。股价受多种因素的影响，公司将继续加强与资本市场投资者的沟通，努力让公司内在价值更好地反映在资本市场的市值表现上，争取为投资者带来更好的回报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617639895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09989","BK0070","002399","BK1191","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591398582","title":"海普瑞选举张平为职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2591398582","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591398582?lang=zh_cn&edition=full","pubTime":"2025-12-16 18:39","pubTimestamp":1765881570,"startTime":"0","endTime":"0","summary":"海普瑞（002399/09989）发布公告，公司于2025年12月16日召开2025年第一次临时股东会，审议通过了关于修订《公司章程》的相关议案。根据修订后的《公司章程》，公司董事会将一个非独立董事席位调整为职工董事席位。张平被选举为公司第六届董事会职工董事，任期至第六届董事会届满之日止。2025年前三季度，海普瑞实现收入41.94亿元，归母净利润5.54亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593149586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK0239","BK0070","002399","09989","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589276842","title":"较A股折价60%，肝素即将走出下行周期海普瑞(09989)现抄底信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589276842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589276842?lang=zh_cn&edition=full","pubTime":"2025-12-06 14:18","pubTimestamp":1765001919,"startTime":"0","endTime":"0","summary":"今年10月30日，海普瑞披露了公司2025年第三季度财报。归属于上市公司股东的净利润5.54亿元，同比下降29.04%。这便是导致此轮生猪下行周期以及肝素下行周期的重要原因。2025年1月，出口价格环比大幅上涨27%。而这一预期已在海普瑞A股上有所反应，目前海普瑞A股股价12.04元，较去年低点6.64元已拉升81.63%。相较之下，海普瑞港股股价虽在同样区间内也有大幅上涨，但仍较A股股价折价60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","159982","002399","BK0070","BK1191","399300","BK0188","09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585498536","title":"海普瑞（002399）披露召开2025年第一次临时股东会通知，11月24日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498536?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:28","pubTimestamp":1763994491,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，海普瑞报收于11.71元，较前一交易日上涨1.21%，最新总市值为171.82亿元。近日，深圳市海普瑞药业集团股份有限公司发布公告，宣布将于2025年12月16日召开2025年第一次临时股东会，会议由董事会召集，现场会议地点为深圳市南山区南海大道3031号兰赫美特酒店二楼宴会厅。股权登记日为2025年12月8日。其中，《关于取消监事会暨修订<公司章程>及配套议事规则的议案》需经出席股东会的股东所持表决权的三分之二以上通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","002399","09989","BK0188","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585467195","title":"海普瑞：关于独立董事任期届满离任暨补选独立董事的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2585467195","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585467195?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:36","pubTimestamp":1763991416,"startTime":"0","endTime":"0","summary":"证券日报网讯11月24日晚间，海普瑞发布公告称，根据有关规定，独立董事在同一上市公司连续任职时间不得超过六年。公司现任独立董事吕川先生连续任职时间即将届满六年。根据前述规定，届满离任后，吕川先生将不再担任包括公司第六届董事会独立董事及董事会专门委员会相应职务（包括提名委员会主任委员、审计委员会委员及战略委员会委员）在内的任何职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511243573239378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0070","BK1191","BK0239","BK0188","002399","09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585465856","title":"海普瑞(09989)：建议选举浦洪为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2585465856","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585465856?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:31","pubTimestamp":1763980279,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)发布公告，董事会建议选举浦洪为独立非执行董事，惟须待股东于临时股东大会上批准后方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","09989","BK0188","002399","BK1191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775840505978,"stockEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0097},{"period":"3month","weight":-0.0837},{"period":"6month","weight":-0.0553},{"period":"1year","weight":0.0888},{"period":"ytd","weight":-0.0433}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳市海普瑞药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2010-05-06","address":"广东省深圳市南山区松坪山郎山路21号","registeredCapital":"146729万元","survey":" 深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投资，开发及商业化。公司的主要产品是依诺肝素钠制剂、肝素钠和依诺肝素钠原料药、分子药物CDMO服务。","listedPrice":148},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海普瑞,002399,海普瑞股票,海普瑞股票老虎,海普瑞股票老虎国际,海普瑞行情,海普瑞股票行情,海普瑞股价,海普瑞股市,海普瑞股票价格,海普瑞股票交易,海普瑞股票购买,海普瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}